Comments on: Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan

Comments on: Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan https://www.novumpr.nl/2016/03/01/exelixis-and-ipsen-enter-into-exclusive-licensing-agreement-to-commercialize-and-develop-novel-cancer-therapy-cabozantinib-in-regions-outside-the-united-states-canada-and-japan/?utm_source=rss&utm_medium=rss&utm_campaign=exelixis-and-ipsen-enter-into-exclusive-licensing-agreement-to-commercialize-and-develop-novel-cancer-therapy-cabozantinib-in-regions-outside-the-united-states-canada-and-japan NovumPR press releases Tue, 01 Mar 2016 08:34:53 +0000 hourly 1 https://wordpress.org/?v=6.8.3